Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Prevention

Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study

Cigarette Smoking-Related Carcinoma

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: PET/CT Imaging of the Head — 2.81; 2.40 %TAD/kg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cigarette Smoking (Behavioral); Computed Tomography (Procedure); Positron Emission Tomography (Procedure); Questionnaire Administration (Other)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Ohio State University Comprehensive Cancer Center
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
PET/CT Imaging of the Head
2.81; 2.40
PRIMARY
PET/CT Imaging of the Chest
6.18; 11.62; 10.35; 5.53
PRIMARY
Puff Volume (mL)
79.35; 73.76
PRIMARY
Puff Duration (s)
2.87; 2.82
PRIMARY
Age of First Tobacco Use
14.58; 14.63
PRIMARY
Years of Tobacco Use
19.58; 16.88
PRIMARY
Years of Regular Use of Nicotine/Tobacco Products
16.83; 15.13
PRIMARY
Past 30 Day Use of Nicotine/Tobacco Products
0; 0.75; 0; 0; 0; 0
PRIMARY
Modified Cigarette Evaluation Questionnaire (mCEQ)
2.28; 1.42; 2.17; 1.38; 0.88; 0.94
PRIMARY
Drug Effects Liking Questionnaire (DEQ)
60.08; 42.88; 51.25; 32.50; 57.25; 31.88
PRIMARY
Modified Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form (QSU)
29.45; 30.15; 16.35; 17.40
PRIMARY
Minnesota Nicotine Withdrawal Scale
9.50; 9.10; 2.60; 2.70
PRIMARY
Exhaled Breath Carbon Monoxide (CO)
2.45; 2.80

Summary

This clinical trial studies the effect of free-base compared with nicotine salt based e-liquids on electronic cigarette (EC) puffing behavior, abuse liability, and deposition and absorption of nicotine in the respiratory tract and rate of uptake in the brain in current EC smokers. The results from this study may provide much needed scientific information to public health officials and regulators.

Eligibility Criteria

Inclusion Criteria

  • A current exclusive e-cigarette user (>= 1 vaping bout per day) for at least the past 6 months (confirmed by NicAlert saliva testing strip)
  • Between 21-50 years old
  • Willing to provide informed consent and abstain from all tobacco and nicotine use for at least 12 hours prior to visits 2 and 3
  • Willing to participate in 3 laboratory visits
  • Read and speak English
  • If utilizing study provided rideshare services, will need to live within 20 miles of Wake Forest University

Exclusion Criteria

  • Self-reported diagnosis of lung disease including asthma, cystic fibrosis, or chronic obstructive pulmonary disease
  • Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  • History of cardiac event or distress within the past 3 months
  • Currently pregnant (as indicated by urine pregnancy test at the start of each laboratory visit), planning to become pregnant, or breastfeeding (women only)
  • Use of other tobacco products (e.g., cigarette, cigar, etc.) > 5 days in the past month
  • Currently engaging in a tobacco product cessation attempt
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05455086). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search